CompletedPhase 4ACTRN12611001229965

Penehyclidine Hydrochloride reduces the incidence of intraoperative awareness

Penehyclidine Hydrochloride reduces the incidence of intraoperative awareness in patients undergoing breast cancer surgery during general anesthesia


Sponsor

Zhiming Tan

Enrollment

900 participants

Start Date

Jan 21, 2010

Study Type

Interventional

Conditions

Summary

Extensive evidence has proved that basal forebrain cholinergic system play extremely important role in explicit memory.Penehyclidine hydrochloride (PHC; (2-hydroxyl-2-cyclopentyl-2-phenyl-ethoxy) quinuclidine) is a new anticholinergic drug with both antimuscarinic and antinicotinic activity while retaining potent central and peripheral anticholinergic activity.The primary purpose of this study is to verify the effectiveness of PHC reducing the incidence of intraoperative awareness. Modified Brice interview was used to assess awareness in the study.


Eligibility

Sex: FemalesMin Age: 15 YearssMax Age: 75 Yearss

Plain Language Summary

Simplified for easier understanding

This study tests whether a medication called penehyclidine hydrochloride can reduce the occurrence of patients becoming aware during surgery. Women aged 15 to 75 undergoing breast cancer surgery under general anesthesia are enrolled.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Patients receive 0.01 mg.kg-1 Penehyclidine Hydrochloride intravenously 30min before surgery

Patients receive 0.01 mg.kg-1 Penehyclidine Hydrochloride intravenously 30min before surgery


Locations(1)

China

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12611001229965